Advanced solid tumor
Conditions
Interventions
Trilaciclib combined chemotherapy group:Administer Trilaciclib intravenously at a dose of 240 mg/m2 for 30 minutes within 4 hours before chemotherapy.
Sponsors
Jiujiang First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Sign a written informed consent before enrollment; 2.Age > 18 years old, both male and female; 3.Pathological examination has clearly diagnosed malignant tumors, which require chemotherapy-based treatment; 4.ECOG score = 0, expected survival = 3 months, follow-up observation for more than 3 months; 5.There were no significant abnormalities in blood routine, liver and kidney function, myocardial enzymes, and electrocardiogram; 6.The subjects voluntarily joined this study, with good compliance, safety and survival follow-up.
Exclusion criteria
Exclusion criteria: 1.History of myelogenous leukemia, myelodysplastic syndrome or associated sickle cell disease; 2.Symptomatic CNS metastasis and/or leptomeningeal disease requiring immediate radiation therapy or steroid treatment; 3.Patients who have undergone surgery or radiotherapy within 4 weeks before the first dose of study drug; 4.Patients with clinical symptoms or diseases of heart failure that cannot be well controlled, such as heart failure at NYHA class 1 or above; 2. Unstable angina pectoris; Myocardial infarction within 36 months; 4. Patients with clinically significant supraventricular or ventricular arrhythmia who require treatment or intervention; 5.History of interstitial lung disease, slowly progressive dyspnea and dry cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary allergic pneumonia, or multiple allergies or peripheral arterial disease such as claudication, Leo Buerger disease. 6.Radiotherapy is required at the same time; 7.Those who have a known history of allergy to the drug components in this protocol; 8.Pregnant or breastfeeding women; 9.The investigator believes that the patient is not suitable for participating in any other conditions of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of neutropenia of grade 3 or higher; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of thrombocytopenia of grade 3 or higher;Overall survival; | — |
Countries
China
Contacts
Public ContactZeng Lingzhi
First Peoples Hospital of Jiujiang
Outcome results
None listed